Glaucoma, the most common cause of irreversible blindness, are a heterogeneous group of optic neuropathies characterized by retinal ganglion cell loss, retinal nerve fiber layer thinning, and visual field loss.[@bib1] Prevalence of glaucoma is expected to increase from 2.7 million to 6.3 million in the United States between 2010 and 2050.[@bib2] Lowering intraocular pressure (IOP) remains the only modifiable risk factor to impede disease progression. The trabecular meshwork (TM) is considered the primary site for outflow resistance via dynamic interactions between TM cells and their extracellular matrix (ECM) microenvironment. In individuals with POAG the TM is demonstrated to be 20-fold stiffer than those without glaucoma.[@bib3]^,^[@bib4] In addition, glaucomatous TM exhibits decreased cellularity,[@bib5] elevated synthesis or deposition of ECM,[@bib6] increased actin contractility,[@bib7] and formation of cross-linked actin networks (CLANs) [@bib8]; this is accompanied by dysregulation of multiple signaling pathways, including but not limited to Wnt/β-catenin, TGFβ, and bone morphogenetic protein (BMP)[@bib3]^,^[@bib7]^,^[@bib9]^--^[@bib11] pathways. Nevertheless, although crosstalk and feedback between multiple pathways are acknowledged, whether these changes are permanent and/or if they are reversible remains to be investigated.

The Wnt signaling pathway is a highly conserved signal transduction pathway that regulates many cellular functions during development: cell proliferation,[@bib12] cell fate determination,[@bib13] apoptosis,[@bib14] cell polarity, and migration.[@bib15] Wnt/β-catenin signaling pathways have been studied extensively in numerous ocular diseases like retinal degeneration, cataract, congenital ocular dysfunctions,[@bib16] and glaucoma.[@bib17]^,^[@bib18] Wnt inhibitors (e.g. secreted frizzled-related protein 1 \[sFRP1\][@bib17] and/or Dickkopf-related protein 1 \[DKK1\]) have been shown to be elevated in glaucoma; overexpression of these proteins is demonstrated to limit aqueous humor (AH) outflow.[@bib19] In previous studies, we showed that sFRP-1 is overexpressed in human trabecular meshwork (hTM) cells cultured on stiffer substrates[@bib20] and Wnt inhibition causes cell stiffening[@bib21]; further, dexamethasone (Dex; a glucocorticosteroid) treatment results in secretion of sFRP1 and DKK1 in the ECM accompanied by ECM stiffening.[@bib9] Independent studies, not related to the Wnt pathway, have shown that the resistance to outflow facility correlates with an increase in TM tissue stiffness.[@bib22] However, it is not known if this pathological phenotype is irreversible and/or subsequently modifiable with intervention.

Recent studies have revealed that pharmacological activation of Wnt signaling plays a major role in various ocular tissues. Wnt activation has been shown to normalize retinal vasculature to help treat familial exudative vitreoretinopathy.[@bib23] Induction of laminin isoforms in human-induced pluripotent stem cell culture promotes their differentiation into neural crest and corneal epithelial cells via Wnt activation.[@bib24] Wnt activation also enhances maintenance of conjunctival epithelial progenitor cells in vitro.[@bib25] Abrogation of stress fibers through Wnt activation was observed in TM cells transfected with wild type myocilin.[@bib26] These studies collectively establish a precedent that Wnt activation may be beneficial to ameliorating the pathology caused by Wnt inhibition in hTM cells. Therefore, we hypothesized that activation of the Wnt pathway subsequent to prolonged Wnt inhibition in primary hTM cells will rescue them toward a healthy phenotype via changes in cell biomechanics, cytoskeletal remodeling, and induction of matrix metalloproteinases (MMPs).

Materials and Methods {#sec2}
=====================

Isolation and Culture of Primary hTM {#sec2-1}
------------------------------------

Primary hTM cells were isolated from donor corneoscleral rims unsuitable for transplant (SavingSight Eye Bank, St. Louis, MO, USA), as described previously.[@bib27] Donor demographics can be found in [Table 1](#tbl1){ref-type="table"}. All experiments were performed in compliance with the tenets of the Declaration of Helsinki. This study is not considered a Human Subject Research, thus is institutional review board (IRB) exempt, because cells were acquired postmortem from de-identified donor tissues. Primary hTM cells were characterized by documenting myocilin response to Dex as recommended ([Supplementary Fig. S1](#iovs-61-6-30_s001){ref-type="supplementary-material"}).[@bib27] For all experiments, hTM cells were used between passages two and six.

###### 

Demographics of Donor Human Corneoscleral Tissues

  hTM       Age/Sex   Experiments Conducted
  ------- ----------- ---------------------------------
  2180      68/male   WB, qPCR, F-actin labeling, AFM
  74M       74/male   WB, qPCR, F-actin labeling, AFM
  57FOS    57/female  WB, qPCR, F-actin labeling
  2003     59/female  WB, F-actin labeling, AFM

Wnt Modulation {#sec2-2}
--------------

The hTM cells were routinely cultured in Dulbecco\'s Modified Eagle Medium : Nutrient Mixture F-12 (DMEM/F12; 1:1) growth media supplemented with 10% fetal bovine serum (FBS; v/v), penicillin/streptomycin. Cells were plated to reach 70 to 80% confluency overnight, following which they were serum deprived by exchanging the growth medium to culture medium containing 0.5% (v/v) FBS for 3 days. Cells were divided into four groups ([Fig. 1](#fig1){ref-type="fig"}): (i) *[Control:]{.ul}* untreated cells cultured for 12 days in culture media containing 0.5% FBS, with media changes every 3 days; (ii) *[Wnt Inhibition:]{.ul}* hTM cells were treated with LGK-974 (10 µM) (Selleckchem, Houston, TX, USA) up to 12 days with (culture) media changes every 3 days. LGK974 is a selective inhibitor of Porcupine *(Porcn)* that blocks the post-translational acylation of Wnt ligands thus inhibiting their secretion.[@bib28] The dose required to inhibit Wnt was based on our prior studies[@bib21]; (iii) *[WntActivation]{.ul}*: cells were treated with LY2090314 (250 nM) (Selleckchem) up to 12 days with (culture) media changes every 3 days. LY2090314 is an inhibitor of GSK-3α/β activity to result in nuclear translocation of β-catenin and thus activation of the pathway.[@bib29] We empirically determined the nontoxic concentration (0--1 µM) required to inhibit pGSK3ß and activate canonical Wnt signaling while cells were \> 80% viable (data not shown); (iv) *[Activation after inhibition]{.ul}*: Wnt pathway was first inhibited with LGK974 (10 µM) treatment for 9 days (with two \[culture\] media changes), following which the pathway was activated by GSK3β inhibition (LY2090314; 250 nM) for 3 days. Following the treatment duration, cells were harvested for gene/protein expression, immunocytochemistry, and atomic force microscopy.

![Schematic representation of treatment regimen. The figure illustrates the treatment regimen for in vitro modulation of Wnt signaling in TM cells. Post-treatment, samples were collected for analysis (AFM, gene/protein expression, immunocytochemistry) on day 12.](iovs-61-6-30-f001){#fig1}

Protein Quantitation by Western Blotting {#sec2-3}
----------------------------------------

Post-treatment, hTM cells were lysed in radioimmunoprecipitation (RIPA) lysis and extraction buffer (Thermo Scientific, Rockford, IL, USA) with protease/phosphatase inhibitor cocktail (Cell Signaling Technology, Danvers, MA, USA) and quantified using the DC protein assay (Bio-Rad, Hercules, CA, USA). Equal concentration of protein (18 µg) were run on 4 to 15% precast polyacrylamide gels (Bio-Rad) and transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature, incubated with respective primary antibodies ([Table 2](#tbl2){ref-type="table"}) at 4 deg Celsius (°C) overnight. Membranes were washed and subsequently incubated in species specific secondary antibody for 45 minutes to 1 hour at room temperature. Protein bands were visualized using ECL detection reagents (Western Bright ECL; Advansta, San Jose, CA, USA) and imaged on a ChemiDoc MP (BioRad) system. Protein band pixel density were quantified using ImageJ Software (<https://imagej.nih.gov/ij/>).

###### 

List of Primary and Secondary Antibodies

  Primary Antibody                          Dilution   Vender
  ----------------------------------------- ---------- ---------------------------------------------
  GAPDH (GA1R)                              1: 10000   Invitrogen, Rockford, IL, USA
  pGSK3β (Tyr216-Tyr279)                    1: 2000    
  pβ-Catenin (T41/S45)                      1: 2500    ABclonal, Woburn, MA, USA
  RhoA (67B9)                               1: 5000    Cell Signaling Technology, Danvers, MA, USA
  CDC42                                     1: 5000    
  pYAP(Ser127) (D9W2I)                      1: 2000    
  pTAZ (Ser89) (E1X9C)                      1: 5000    
  YAP1                                      1: 2500    Novus Biologicals, Centennial, CO, USA
  TAZ/WWTR1                                 1: 5000    
  **Secondary antibody**                               
  Peroxidase labeled goat anti-rabbit IgG   1:10.000   KPL, Gaithersburg, MD, USA
  Peroxidase labeled goat anti-mouse IgG    1:10.000   

Gene Expression by Quantitative Real Time PCR {#sec2-4}
---------------------------------------------

Post-treatment, hTM cells were lysed and mRNA was extracted using the Purelink RNA mini Kit (Life Technologies, Carlsbad, CA, USA). RNA (1 µg) was converted to cDNA using a high capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). Quantitative real-time PCR was performed on 20 ng of the cDNA with gene specific primers ([Table 3](#tbl3){ref-type="table"}) and the PowerUp SYBR Green Master Mix kit (Applied Biosystems) in total volumes of 10 µL per reaction using a CFX Connect Real-time System from Bio-Rad Laboratories (Bio-Rad). The cycle threshold (C~t~) values obtained from the qPCR equipment and analyzed using the 2^−ΔΔCt^ method with *GAPDH* as the housekeeping gene.

###### 

List of Primers Used for qPCR

  Gene Name   Sequence (5′-3′)                                          Size (bp)   Gene Accession
  ----------- --------------------------------------------------------- ----------- ----------------
  *DKK1*      F: AGCGTTGTTACTGTGGAGAAG R: GTGTGAAGCCTAGAAGAATTACTG      82          NM_012242.4
  *sFRP1*     F: AGATGCTTAAGTGTGACAAGTTCC R: TCAGATTTCAACTCGTTGTCACAG   130         NM_003012.5
  *AXIN2*     F: CAGATCCGAGAGGATGAAGAGA R: AGTATCGTCTGCGGGTCTTC         128         NM_001363813.1
  *LEF1*      F: GACGAGATGATCCCCTTCAA R: CGGGATGATTTCAGACTCGT           135         NM_016269.5
  *SPARC*     F: GTGCAGAGGAAACCGAAGAG R: AAGTGGCAGGAAGAGTCGAA           202         NM_001309444.2
  *MYOC*      F: TGTCCGCCAGGTTTTTGAGT R: TGGAAATAGAGGCTCCCCGA           129         NM_000261.2
  *CTGF*      F: ACCTGTGCCTGCCATTACAA R: GCTTCATGCCATGTCTCCGT           90          NM_001901.3
  *LOX*       F: CGACCCTTACAACCCCTACA R: AAGTAGCCAGTGCCGTATCC           117         NM_002317.7
  *TGM2*      F: CTCAGGGCTCACAGTGGAT R: AGGGGTCCTATCTCTCATCCTG          75          NM_001323316.1
  *MMP1*      F: CCAGGCCCAGGTATTGGAGGGG R: GGCCGAGTTCATGAGCTGCA         106         NM_002421.4
  *MMP2*      F: ATAACCTGGATGCCGTCGT R: AGGCACCCTTGAAGAAGTAGC           63          NM_004530.6
  *MMP9*      F: GAACCAATCTCACCGACAGG R: GCCACCCGAGTGTAACCATA           67          NM_004994.3
  *MMP14*     F: CACCATGAAGGCCATGAGGC R: GTATGTGGCATACTCGCCCA           175         NM_004995.4
  *TIMP1*     F: ACTACCTGCAGTTTTGTGGCT R: CTGGTCCGTCCACAAGCAA           162         NM_003254.3
  *PAI1*      F: CCACTTCTTCAGGCTGTTCC R: CCGTTGAAGTAGAGGGCATT           186         NM_000602.5
  *GAPDH*     F: GGTGAAGGTCGGAGTCAAC R: CCATGGGTGGAATCATATTG            153         NM_001289745.3

F-actin Visualization and Immunostaining {#sec2-5}
----------------------------------------

Post-treatment, hTM cells were fixed in 4% paraformaldehyde in PBS for 30 minutes at room temperature and further permeabilized/blocked in blocking solution (5% bovine serum albumin, 0.1% Triton X-100 in PBS) for 1 hour at room temperature. Some coverslips (2 coverslips each per cell strain) were incubated Alexa Fluor 594 phalloidin (ThermoFisher Scientific, Eugene, OR, USA) for 20 minutes at room temperature, whereas others (2 coverslips each per cell strain) were incubated with primary antibodies against YAP1 or TAZ (1:250 dilution) at 4°C overnight. This was followed by incubation with species-appropriate secondary antibody conjugated with DyLight 488 (Invitrogen, Rockford, IL, USA) for (1:500 dilution) 1 hour at room temperature. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (Fisher Scientific, CA, USA) and mounted using mowiol (mowiol is an aqueous mounting medium comprised of polyvinyl alcohol (Mowiol 4-88; Sigma-Aldrich, St. Louis, MO, USA) and glycerol made in 0.2M Tris-Cl buffer (pH 8.5); DABCO (1,4-diazabicyclo-\[2,2,2\]-octane) was used as anti-fade). Immunofluorescent images were then captured using an inverted fluorescent microscope (Leica Microsystems AG, Germany) with a ×20 or ×40 objective. For each immunolabelled glass coverslip, 5 to 10 random locations were imaged for all donor strains (*n* = 4). Due to the qualitative nature of imaging, no quantitative measurements were performed at this time. In addition, for each condition per cell strain, the height of 100 cells were determined using *z-*stack. As appropriate, representative images from a single field of view for a single donor are illustrated in the results section(s).

Cellular Biomechanics by Atomic Force Microscopy {#sec2-6}
------------------------------------------------

Elastic moduli of cells were determined as described previously.[@bib21]^,^[@bib30] Briefly, force-distance curves were obtained in contact mode using PNP-TR cantilevers (nominal spring constant 0.32 N/m; Nano and More, Watsonville, CA, USA) with a pyramidal tip. For all samples (*n* = 4 donor strains), force curves were obtained from at least 10 cells with 5 force curves for each cell. Elastic modulus was determined using Sneddon model; details of the equation are described elsewhere.[@bib31] Data are represented as violin plots pooling all force curves from each donor strain per treatment.

Statistical Analysis {#sec2-7}
--------------------

Statistical comparison for mechanics, protein, and gene expression among the various groups was done using 1-way ANOVA with Dunnett\'s multiple post hoc comparisons compared with control cells was used to determine significance. In addition, using *t*-test we compared the results between "Wnt inhibition" and "Wnt activation after inhibition" groups. Results for all comparisons are indicated in the plots and described within the figure legends.

Results {#sec3}
=======

Modulation of Wnt Signaling Pathway {#sec3-1}
-----------------------------------

The concentration of Wnt inhibitor (LGK974; 10 µM) was based on our previous study.[@bib21] Effective nontoxic concentration of Wnt activator (LY2090314; 250 nm) was determined empirically in a dose-response manner. Wnt inhibition resulted in overexpression of pGSK3β (1.44-fold; *P* \< 0.05) and pβ-Catenin (1.73-fold; *P* \< 0.05) compared with the control group. Consequent to treatment with LY2090314, significant downregulation in pGSK3β levels were observed compared with the control group (0.3-fold; *P* \< 0.01) ([Fig. 2](#fig2){ref-type="fig"}A). *DKK1* and *sFRP1* were used as markers for Wnt antagonism.[@bib19] No significant changes were seen in *DKK1* and *sFRP1* expression after Wnt inhibition, but they remarkably decreased with activation alone (0.37-fold *P* \< 0.05, 0.19-fold *P* \< 0.01, respectively) or with activation after inhibition (0.3-fold, *P* \< 0.05, 0.2-fold, *P* \< 0.01, respectively) compared with the untreated control group ([Fig. 2](#fig2){ref-type="fig"}B). *AXIN2*[@bib32] and lymphoid enhancer-binding factor 1 (*LEF1*),[@bib33] transcriptional target genes for Wnt, were used as markers of Wnt signaling activation. The mRNA expression of both genes were significantly upregulated with Wnt activation after inhibition (6.7-fold, *P* \< 0.001 and 3.7-fold, *P* \< 0.001, respectively) and with activation only (6.35-fold, *P* \< 0.001 and 3.8-fold *P* \< 0.001, respectively) ([Fig. 2](#fig2){ref-type="fig"}C). These results collectively demonstrate successful modulation of Wnt signaling in hTM cells.

![LGK974 inhibits while LY2090314 activates Wnt signaling in hTM cells. Primary hTM cells were treated with/without Wnt modulators over 12 days. Whole cell lysates were collected for Western blotting (*n* = 4 donor strains) and gene expression (*n* = 3 donor strains). (**A**) Representative Western blot from a single donor documenting changes in pβ-Catenin (S45/Thr41) and pGSK3β protein expression with GAPDH as loading control. Densitometric analysis of blots document a decrease in the pβ-Catenin and pGSK3β levels with Wnt activation. (**B**) Wnt activation after 9-days of Wnt inhibition resulted in reduced *DKK1* and *sFRP1* gene expression. (**C**) Relative mRNA expression of *AXIN2* and *LEF1* genes were significantly elevated with Wnt activation regardless of Wnt inhibition. The treatment regimen are as follows: − − = indicates no treatment; + − = indicates cells were treated with only LGK974; + + = indicates cells were first treated with LGK974 for 9 days following which they were treated with LY2090314 for 3 days; − + = corresponds to cells treated with only LY2090314. Data presented in histograms are mean ± standard deviation (SD). Asterisk (\*) are used to show comparisons made my 1-way ANOVA followed by Dunnett\'s post hoc multiple comparison compared with control; \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. Hash symbol (\#) denotes Student\'s *t*-test comparing the results between "Wnt inhibition" and "Wnt activation after inhibition"; ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01; ^\#\#\#^*P* \< 0.001.](iovs-61-6-30-f002){#fig2}

Wnt Activation Alters the Cytoskeletal Dynamics {#sec3-2}
-----------------------------------------------

Next, we examined whether Wnt modulated Rho GTPase: RhoA and CDC42 in hTM cells. Rho GTPases regulate cell motility, cytoskeletal dynamics,[@bib34] smooth muscle contractile properties, cell morphology, and trafficking.[@bib35]^,^[@bib36] Significant upregulation of RhoA levels after Wnt inhibition (1.6-fold *P* \< 0.05) was observed. In contrast, CDC42 were downregulated (0.75-fold, *P* \< 0.05) when Wnt was inhibited ([Fig. 3](#fig3){ref-type="fig"}). Wnt activation, however, did not appear to modulate RhoA/CDC42 proteins levels when compared with untreated cells. However, in comparison with the Wnt inhibited group, RhoA was suppressed (*P* \< 0.05) and CDC42 (*P* \< 0.05) was upregulated with Wnt activation following Wnt inhibition. In general, these findings suggest that Wnt activation after inhibition rescues cells from aberrant cytoskeletal protein expression toward a normal phenotype.

![Wnt modulation alters RhoGTPases that regulate cytoskeletal dynamics. Representative Western blot from a single donor documenting changes in expression levels of RhoA and CDC42 protein expression (*n* *=* 4 donor strains). The treatment regimen are as follows: − − = indicates no treatment; + − = indicates cells were treated with only LGK974; + + = indicates cells were first treated with LGK974 for 9 days following which they were treated with LY2090314 for 3 days; − + = corresponds to cells treated with only LY2090314. Densitometric analysis of blots are illustrated as histograms as mean ± standard deviation (SD). Asterisk (\*) are used to show comparisons made my 1-way ANOVA followed by Dunnett\'s post hoc multiple comparison compared with control; \**P* \< 0.05; \*\**P* \< 0.01, \*\*\**P* \< 0.001. Hash symbol (\#) denotes Student\'s *t*-test comparing results between "Wnt inhibition" and "Wnt activation after inhibition"; ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01; ^\#\#\#^*P* \< 0.001.](iovs-61-6-30-f003){#fig3}

Activation of Wnt Resolves CLAN Like Structures {#sec3-3}
-----------------------------------------------

RhoGTPases are enzymes that regulate the nucleation and formation of filamentous actin (F-actin). Subsequent to changes in RhoA and CDC42, we next determined if there indeed were significant changes in F-actin in hTM cells. Wnt inhibition resulted in the formation of CLAN-like structures compared with presence of stress-fibers only in control samples. These complex geodesic structures were subsequently resolved with Wnt activation ([Fig. 4](#fig4){ref-type="fig"}). These data further support the finding that activation of Wnt signaling subsequent to Wnt inhibition may resolve aberrant cytoskeletal remodeling.

![Activation of Wnt pathway resolves CLAN-like structures. Primary hTM cells (*n* = 4 donor strains) cultured on glass coverslips were treated with/without Wnt signal modulators for 12 days following which cells were fixed and stained with Phalloidin to visualize F-actin. There were 10 random fields per coverslip per donor strain that were imaged. Representative image demonstrates F-actin (*red*), and nuclei (*blue*) labeling respectively. Insets demonstrate alterations in actin cytoskeleton in gray scale. Scale bar indicates 50 µm.](iovs-61-6-30-f004){#fig4}

Wnt Activation After Inhibition Reduces Cell Stiffness {#sec3-4}
------------------------------------------------------

Functional consequences to RhoGTPases and F-actin reorganization were evaluated by documenting cell mechanics. As expected and consistent with our previous study,[@bib21] Wnt inhibition increased cellular stiffness compared with control cells (11.86 kPa vs. 4.96 kPa, *P* \< 0.01). Cells with Wnt activation alone (3.54 kPa, *P* \< 0.05) were significantly softer compared with control cells. Elastic moduli of cells with Wnt activation after inhibition (4.19 kPa) was not significantly different from the control group but was significantly lower compared with Wnt inhibited group (*P* \< 0.01) ([Fig. 5](#fig5){ref-type="fig"}A). The elastic moduli of cells were obtained over the tallest portion of a cell (i.e. at the location of the nucleus). We were curious if Wnt modulation influenced cell height. We observed that with Wnt activation (either alone or after inhibition) the cell height trended toward an increase, although statistical significance was not achieved ([Fig. 5](#fig5){ref-type="fig"}B). We performed Pearson\'s correlation ([Fig. 5](#fig5){ref-type="fig"}C) to determine if a relationship existed between cell height and elastic modulus for each treatment group. We observed significant correlation between the two variables for Wnt inhibition (*P* \< 0.01) and Wnt activation after inhibition groups (*P* \< 0.05). These findings demonstrate that cellular stiffness was significantly decreased when Wnt was activated even after 9 days of inhibition.

![Activation of Wnt softens hTM cells. (**A**) Primary hTM cells were cultured in FluoroDish tissue culture dishes with/without Wnt modulators for 12 days. Cell mechanics were determined by atomic force microscopy. Data are represented as violin plots with mean ± standard error in mean (SEM) indicated in the plot. Results are data pooled from all force curves obtained from the four donor strains. (**B**) The height of hTM cells in the various treatment groups was calculated from the highest point of the cell above the nucleus to the underlying substratum. Results are from at least 100 cells per treatment group for each donor strain. Data are represented with individual data points as dots overlaid with mean ± standard error in mean (SEM) from *n* = 3 biological donor strains. The treatment regimen are as follows: − − = indicates no treatment; + − = indicates cells were treated with only LGK974; + + = indicates cells were first treated with LGK974 for 9 days following which they were treated with LY2090314 for 3 days; − + = corresponds to cells treated with only LY2090314. Asterisk (\*) are used to show comparisons made my 1-way ANOVA followed by Dunnett\'s post hoc multiple comparison compared with control; \**P* \< 0.05; \*\**P* \< 0.01. Hash symbol (\#) denotes Student\'s *t*-test comparing results between "Wnt inhibition" and "Wnt activation after inhibition"; ^\#\#^*P* \< 0.01. (**C**) Pearson\'s correlation to demonstrate relationship between elastic moduli of cells versus cell height. Data were pooled from all four donor strains for each treatment.](iovs-61-6-30-f005){#fig5}

Wnt Activation Alters the Expression of Hippo Pathway Effectors {#sec3-5}
---------------------------------------------------------------

We have previously documented that both YAP and TAZ are expressed in hTM cells and may be differentially modulated by substratum stiffness in vitro.[@bib20] Here, we determined if modulation of Wnt signaling was associated with expression and subcellular localization of these proteins. When normalized to total protein levels of YAP1, significant inhibition of phosphorylated YAP1 (pYAP \[S127\]; *P* \< 0.05) was observed with Wnt inhibition ([Fig. 6](#fig6){ref-type="fig"}A) accompanied by increased expression of nuclear YAP1 ([Fig. 6](#fig6){ref-type="fig"}B) compared with untreated controls. Similarly, Wnt inhibition resulted in greater nuclear accumulation of TAZ ([Fig. 6](#fig6){ref-type="fig"}B) although no differences were observed in the ratio of pTAZ to total TAZ. With activation of Wnt, significant increases in ratios of phosphorylated YAP1/TAZ to total YAP1/TAZ, respectively, were observed (*P* \< 0.001 for YAP1, and *P* \< 0.05 for TAZ; see [Fig. 6](#fig6){ref-type="fig"}A*)* accompanied with more cytosolic retention of these proteins (see [Fig. 6](#fig6){ref-type="fig"}B). Overall, the data demonstrates that Wnt activation leads to increased levels of phosphorylation and cytosolic retention of YAP1/TAZ.

![Wnt modulation affects YAP/TAZ phosphorylation and localization. (**A**) Representative Western blot analysis (*n* = 3 donor strains) demonstrating the effects of Wnt modulation on the ratio of phosphorylated protein levels to total protein levels for the hippo pathway effectors YAP1/TAZ. Wnt activation regardless of Wnt inhibition significantly increased their cellular phosphorylation levels. Histograms show average of relative levels of pYAP1:YAP1 or pTAZ:TAZ corrected for GAPDH levels. (**B**) Representative image demonstrating the subcellular localization of YAP1 or TAZ (*green*) and nuclei (*blue*) in cells across the treatment groups. *Yellow arrows* indicate localization of YAP1 or TAZ in the nucleus after Wnt inhibition. The treatment regimen are as follows: − − = indicates no treatment; + − = indicates cells were treated with only LGK974; + + = indicates cells were first treated with LGK974 for 9 days following which they were treated with LY2090314 for 3 days; − + = corresponds to cells treated with only LY2090314. Asterisks (\*) are used to show comparisons made my 1-way ANOVA followed by Dunnett\'s post hoc multiple comparison compared with control; \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. Hash symbol (\#) denotes Student\'s *t*-test comparing results between "Wnt inhibition" and "Wnt activation after inhibition"; ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01; ^\#\#\#^*P* \< 0.001.](iovs-61-6-30-f006){#fig6}

Effects of Wnt Alteration Changes the ECM Expressions {#sec3-6}
-----------------------------------------------------

We next investigated whether Wnt modulation influenced ECM expression in hTM cells. The mRNA expression levels of secreted protein acidic and rich in cysteine (SPARC) and connective tissue growth factor (CTGF; downstream target of YAP/TAZ) were significantly downregulated with Wnt activation alone (SPARC: 0.54-fold, *P* \< 0.05, CTGF: 0.08-fold, *P* \< 0.001) or with Wnt activation after inhibition (0.49-fold, *P* \< 0.05, 0.06-fold, *P* \< 0.001) ([Fig. 7](#fig7){ref-type="fig"}A), whereas Wnt inhibition alone did not affect expression of these genes. On the other hand, where Wnt inhibition overexpressed ECM cross-linking genes (LOX: 1.35-fold; TGM2: 2.1-fold, *P* \< 0.05), Wnt activation significantly reduced their expression either by itself (LOX: 0.32-fold, *P* \< 0.01; TGM2: 0.44-fold, *P* \< 0.05) or when activated after Wnt inhibition (LOX: 0.19-fold, *P* \< 0.001; *TGM2:* 1.0-fold, *P* \< 0.05) ([Fig. 7](#fig7){ref-type="fig"}B).

![Wnt modulation alters expression of ECM regulating genes. Primary hTM cells (*n* = 3 donor strains) were cultured with/without Wnt signal modulators for 12 days following which mRNA was isolated and qPCR was performed. (**A**) Matricellular genes *SPARC* and *CTGF* were significantly downregulated with Wnt activation. (**B**) ECM cross-linking genes (*LOX*, and *TGM2*) were elevated with Wnt inhibition and significantly inhibited with subsequent Wnt activation. (**C**) ECM turnover proteins *MMPs1*, *9*, and *14* were upregulated with Wnt activation but repressed with Wnt inhibition. Likewise, inhibitors of MMPs (*TIMP1* and *PAI-1*) were remarkably reduced with Wnt activation. The treatment regimen are as follows: − − = indicates no treatment; + − = indicates cells were treated with only LGK974; + + = indicates cells were first treated with LGK974 for 9 days following which they were treated with LY2090314 for 3 days; − + = corresponds to cells treated with only LY2090314. Asterisks (\*) are used to show comparisons made my 1-way ANOVA followed by Dunnett\'s post hoc multiple comparison compared with control; \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. Hash symbol (\#) denotes Student\'s *t*-test comparing results between "Wnt inhibition" and "Wnt activation after inhibition"; ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01;, ^\#\#\#^*P* \< 0.001.](iovs-61-6-30-f007){#fig7}

Next, we investigated changes in genes involved in ECM turnover. Wnt modulation did not significantly alter *MMP2* expression. Where Wnt inhibition downregulated MMP1 (0.09-fold, *P* \< 0.001), its expression was upregulated when Wnt was activated alone (2.83-fold, *P* \< 0.05) or when activated following Wnt inhibition (2.58-fold, *P* \< 0.001). Similarly, MMP9 and MMP14 were all upregulated with Wnt activation either by itself (13.68-fold, *P* \< 0.05, or 5.37-fold, *P* \< 0.001, respectively) or when activated after Wnt inhibition (9.15-fold, *P* \< 0.01, or 5.02-fold, *P* \< 0.001, respectively).

Concurrently, inhibitor of metalloproteinase 1 (TIMP1) was upregulated with Wnt inhibition (1.9-fold, *P* \< 0.05), but was significantly downregulated when Wnt was activated alone (0.30-fold, *P* \< 0.001) or when activated following Wnt inhibition (0.5-fold, *P* \< 0.001) ([Fig. 7](#fig7){ref-type="fig"}C). Plasminogen activator inhibitor-1 (PAI-1), a serine protease inhibitor, was also downregulated after Wnt activation alone (0.33-fold, *P* \< 0.001), or activation following Wnt inhibition (0.34-fold, *P* \< 0.001).

Effects of Wnt Modulators Change in Myocilin Expressions {#sec3-7}
--------------------------------------------------------

Myocilin (MYOC), a matricellular protein abundantly expressed in glaucomatous TM,[@bib37] was significantly altered both at gene and protein levels. Gene expression was reduced with Wnt activation (0.24-fold, *P* \< 0.01) alone or with activation after inhibition (0.22-fold, *P* \< 0.01) compared to the control group ([Fig. 8](#fig8){ref-type="fig"}A). Although gene expression trended to be overexpressed with Wnt inhibition, due to large donor-to-donor variability, statistical significance was not achieved. However, the MYOC protein level was significantly upregulated (2.12-fold, *P* \< 0.01) with Wnt inhibition ([Fig. 8](#fig8){ref-type="fig"}B) while being reduced with Wnt activation (0.23-fold, *P* \< 0.01) alone or with activation after inhibition (0.46--fold, *P* \< 0.01) compared to the control group.

![Wnt modulation significantly alters MYOC expression. Myocilin expression with Wnt modulation was documented by (**A**) qPCR (*n* = 3 donor strains), and (**B**) Western blotting (*n* = 4 donor strains). Both mRNA and proteins levels of MYOC were drastically reduced with Wnt activation. However, increases in *MYOC* expression after Wnt inhibition were statistically significant only at the protein level. The treatment regimen are as follows: − − = indicates no treatment; + − = indicates cells were treated with only LGK974; + + = indicates cells were first treated with LGK974 for 9 days following which they were treated with LY2090314 for 3 days; − + = corresponds to cells treated with only LY2090314. Asterisks (\*) are used to show comparisons made my 1-way ANOVA followed by Dunnett\'s post hoc multiple comparison compared with control; \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. Hash symbol (\#) denotes Student\'s *t*-test comparing results between "Wnt inhibition" and "Wnt activation after inhibition"; ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01; ^\#\#\#^*P* \< 0.001.](iovs-61-6-30-f008){#fig8}

Discussion {#sec4}
==========

POAG is the most common type of glaucoma leading to irreversible vision loss with IOP as the only modifiable risk factor. The TM is considered a major regulator of aqueous humor outflow facility to maintain normal levels of IOP. Damage to cells in the TM is correlated with ocular hypertension and progression of glaucoma. Secreted factors (such as cytokines and growth factors) concurrent with changes in gene/protein expression in TM cells orchestrate the remodeling of ECM, and together these have been associated with POAG.[@bib38] The molecular mechanisms underlying the etiology and progression of TM pathology, however, remains unclear. Among the many pathways suggested to be dysregulated in disease, the Wnt signaling pathway is one that is strongly implicated in glaucomatous TM.[@bib19]^,^[@bib21] This pathway is conserved, critical during development, and regulates cell fate during embryogenesis; but is also implicated in playing a crucial role in tissue homeostasis.[@bib39] We have previously demonstrated that chronic treatment of normal TM cells with Dex results in the increased secretion of Wnt inhibitors (DKK1 and sFRP1) into the ECM in vitro.[@bib9] Overexpressing Wnt antagonists, sFRP1 and DKK1, in mice can result in elevated IOP, reduced outflow facility, and degeneration of TM tissues.[@bib17]^,^[@bib19] In this study, through inhibition of *Porcn* using LGK974, we do not observe any significant changes in gene expression for *sFRP1/DKK1.* This is likely due to a reduction in secretion of Wnt ligands, mediated by suppression of *Porcn'* acyltransferase activity, leading to a disruption in an important feedback loop. Nevertheless, as expected, an upregulation in phosphorylated β-catenin accompanied with increased phosphorylation of GSK3β demonstrates Wnt inhibition.[@bib39]^--^[@bib41] Inhibition of pGSK3β, with LY2090314, and subsequent activation of canonical Wnt/β-catenin signaling was confirmed through overexpression of *AXIN2*[@bib42] and *LEF1*[@bib33] regardless of prior Wnt inhibition; this was accompanied by significant repression of Wnt inhibitors, *sFRP1* and *DKK1*. This is important when we consider our findings from a prior study[@bib21] where cells remained in a disruptive state, despite removal of Wnt inhibitor, prolonging a pathologic phenotype. Thus, our approach of activating Wnt after Wnt inhibition may break this cycle and facilitate reversal of TM cells toward normalcy.

Wnt Modulation Alters Cytoskeletal Dynamics, Mechanotransduction, and Cellular Biomechanics {#sec4-1}
-------------------------------------------------------------------------------------------

RhoGTPases are an important effector of the noncanonical Wnt planar cell polarity (PCP) pathway.[@bib43] The PCP signaling plays a key mediator in orchestrating cell, tissue organization, and its function are mediated via changes in the actin cytoskeleton. Our data demonstrates that overexpression of RhoA caused by Wnt inhibition can be reversed by subsequent Wnt activation. This is consistent with previous studies that document RhoA inactivation through the activation of canonical Wnt/β-catenin signaling in the murine cancer cells.[@bib44]^,^[@bib45] Activation of RhoGTPases are also associated with nucleation of F-actin which may adversely stiffen cells. Consistent with our previous study,[@bib21] here, we demonstrated that Wnt inhibition results in significant cell stiffening, which is reversed with subsequent Wnt activation. In fact, cells were slightly yet significantly softer with Wnt activation than untreated or Wnt inhibited cells. Noncanonical Wnt activation has been demonstrated to induce CLAN formation, which is reversible with Ror2 knockdown.[@bib46] Currently though, there is no causal link to establish that CLANs are profibrotic, compared with nonglaucomatous TM cells glaucomatous TM cells present with an increase in CLANs.[@bib47]^--^[@bib49] In addition, steroid and TGFβ2 treatment of TM cells induce CLAN formation[@bib50]^--^[@bib52]; both steroid and TGFβ2 have been associated with elevations in IOP, increased actin contractility and Rho kinase activity. In addition, β1 and β3 integrins have been shown to enhance CLAN formation.[@bib53] Induction of CLANs have been associated with reduced TM proliferation, migration, and phagocytosis[@bib54]^--^[@bib56]; features that have been attributed as a profibrotic dysfunction of the TM. Although we specifically did not count the number of cells that form CLANs, here, we observed dramatic changes in F-actin organization, with Wnt inhibition, resembling CLAN-like geodesic structures that has been speculated to be associated with stiffer cells.[@bib54] Whereas Mao et al. demonstrated that activation of canonical Wnt via Wnt3A had no influence on CLAN formation,[@bib19] Webber et al.[@bib57] demonstrated that Wnt3a, increased K-cadherin expression to reduce transcellular resistance and ocular hypertension. Our data show that Wnt activation via inhibition of pGSK3β was enough to resolve the complex CLAN-like reorganization. We thus speculate that the method used to activate canonical Wnt signaling may be important and may result in different downstream targets being differentially modulated. Further studies are required to validate this hypothesis, and to definitively tie CLANs with TM pathology and biomechanical changes. However, relaxation of the actin cytoskeleton is thought to decrease cellular contractility, and increase AH outflow,[@bib58] thus supporting our result that Wnt activation may be beneficial to restoring TM cell function. Wnt inhibition also resulted in inhibition of CDC42 here, which can adversely impact proliferation, polarity, migration, and differentiation of cells disrupting homeostasis.[@bib59] In addition, suppression of CDC42 is thought to disrupt formation of tunneling nanotubes (TNTs)[@bib60] that are essential for intercellular communication in TM culture.[@bib61] Again, activation of Wnt was able to rescue CDC42 suppression in TM cells.

RhoGTPases are thought to regulate signal transduction via mechanotransducers and transcriptional coactivators of the Hippo pathway, YAP, and TAZ.[@bib62]^,^[@bib63] Dupont et al.[@bib64] demonstrated that transcriptional activity of YAP/TAZ requires Rho activation and tension in the cytoskeleton. In line with this, Wnt inhibition resulted in a decrease in the phosphorylation of YAP at S127 and TAZ at S89 triggering its nuclear localization. Nuclear YAP/TAZ can constitutively trigger overexpression of ECM crosslinkers (TGM2 and LOX),[@bib64]^--^[@bib66] and connective tissue growth factor (CTGF) and TGFβ, two growth factors that have been associated with glaucoma.[@bib67]^--^[@bib70] Subsequent activation of canonical Wnt resulted in corresponding increases in pYAP(S127)/pYAZ(S89) and their cytoplasmic retention suggesting a resultant inhibition of their transcriptional function. Curiously, cytoplasmic YAP/TAZ, widely documented in cells cultured on softer substrates,[@bib64] is reflective of softer cells considering cells cultured on softer substrates are intrinsically softer.[@bib71]^,^[@bib72] Collectively, our data demonstrate that activation of Wnt decreases RhoA, restores CDC42, resolves complex F-actin reorganization, softens cells, and is associated with cytoplasmic YAP/TAZ.

Wnt Modulation Dynamically Alters Extracellular Matrix Regulatory Gene Expression {#sec4-2}
---------------------------------------------------------------------------------

Because one of the major effects of Wnt inhibition is an increase in resistance to AH outflow, we next explored if activating Wnt after its inhibition beneficially modulates genes that regulate the ECM. Here, we document that Wnt inhibition upregulated the expressions of multiple ECM genes (*SPARC*, *CTGF*, and *MYOC*) and ECM crosslinkers (*TGM2* and *LOX*) while simultaneously inhibiting expression of MMPs (*MMP1* and *MMP9*). Interestingly, *CTGF*, *TGM2*, *LOX*, and *PAI-1* are all downstream transcriptional targets of YAP/TAZ.[@bib64]^--^[@bib66] SPARC is a multifunction protein that modulates cell shape, adhesion, interactions with the ECM,[@bib73] and affects the expression of MMPs and some growth factors.[@bib74] In fact, overexpression of SPARC increased IOP via alterations in the ECM.[@bib75] Similarly, chronic upregulation of CTGF leads to cellular stress, increase in TM ECM actin-mediated contractility[@bib76] and ocular hypertension in mice.[@bib69] Mutations in myocilin have been associated with POAG, cause endoplasmic reticular stress and elevate IOP.[@bib77]^--^[@bib80]

Biomechanical properties of the ECM depend not only on composition, but also on organization and post-translational modifications, such as crosslinking.[@bib81] The LOX family proteins catalyze the crosslinking of collagens and elastin through oxidative deamination of lysine and hydroxylysine residues, which stabilize collagen and elastin fibers in the ECM.[@bib82]^,^[@bib83] Transglutaminase enzymes catalyze the post-translational modification of proteins through the formation of isopeptide bonds resulting in crosslinking of ECM proteins, including fibronectin, collagen, laminin, and elastin.[@bib84]^--^[@bib86] Thus, crosslinking of ECM proteins prevents proteolytic breakdown and results in decreased ECM turnover, ECM accumulation, and tissue stiffness.[@bib87] Overexpression of tissue transglutaminase 2 (TGM2) has been shown to elevate IOP in mice.[@bib88]^,^[@bib89] Keller et al. demonstrated that ECM turnover initiated by MMPs in the TM were necessary to maintain the outflow facility and homeostasis.[@bib90]^,^[@bib91] Altogether, Wnt inhibition resulted in deleterious effects on ECM regulatory genes. Activation of canonical Wnt signaling, irrespective of whether Wnt inhibition was present, reversed the above observed changes. We saw potent elevation in *MMPs*, downregulation of *CTGF*, *SPARC*, *MYOC*, *LOX*, and *TGM2* accompanied by significant downregulation of inhibitors of *MMPs*, such as *TIMP1* and *PAI-1*. These suggest that the ability of cells to restore ECM homeostasis may not be irreversibly damaged; thus, intervention to restore outflow facility may be effective.

Limitations {#sec4-3}
-----------

Although the results presented here are consistent with each other, this study is not without limitations. First, all of our experiments were performed in vitro to identify molecular changes in the signaling pathway*.* Thus, extrapolations of our data to what may be observed in vivo, or ex vivo should be done so cautiously considering functional changes in outflow resistance and facility were not determined. Second, we use small molecule compounds to modulate Wnt signaling. Whereas such use has numerous advantages, their effects are dose-time dependent, and, thus, may inflict off-target effects when used for longer periods of time. This is especially true because the Wnt pathways intersects with numerous other signaling pathways. Additional studies using a genetic approach with targeted gene silencing/knock-in/mutations may be essential to dissect a causal relationship between the Wnt and YAP/TAZ pathways. Finally, all of our in vitro studies were performed on glass/tissue culture plastic whose mechanical and chemical properties are far removed from the native microenvironment that cells perceive in vivo. Thus, future investigations will be required by culturing cells on hydrogels of varying stiffness or on cell derived matrices/engineered scaffolds mimicking the properties of the native TM.

Conclusion {#sec5}
==========

In summary ([Fig. 9](#fig9){ref-type="fig"}), we demonstrate here that perturbing secretion of Wnt ligands by targeting *Porcn* results in triggering pathology in TM cells in the form of cytoskeletal remodeling, cell stiffness, overexpression of ECM genes, upregulation of ECM crosslinkers, and decreases in MMPs with simultaneous overexpression of inhibitors of MMPs; these changes may partially be due to translocation of YAP/TAZ to the nucleus. Subsequently, we demonstrate that this pathologic phenotype is reversible with canonical Wnt activation via inhibition of pGSK3β. Specifically, this resulted in cell softening, resolution of CLAN-like structures, cytoplasmic retention of YAP/TAZ, decreased expression of ECM crosslinkers, and inhibitors of MMPs with upregulation of specific MMPs responsible for ECM turnover. We thus speculate that GSK3β may be potent molecular target for the reduction of IOP.

![Schematic summary of the effect of Wnt modulation on TM cells. TM cells were treated with LGK974 to inhibit *Porcn* in the endoplasmic reticulum (ER) to block post-translational acylation of Wnt ligands, thus restricting their secretion. This results in the increased formation of CLAN-like structures, elevated cell stiffness, transcriptional activation of YAP/TAZ to overexpress *TGM2*, *CTGF*, *LOX*, and suppress *MMPs*. Subsequently, treatment of TM cells with GSK3β inhibitor, LY2090314, results in nuclear translocation of β-catenin to activate its transcription. This results in the elevated expression of downstream target genes like *AXIN2*, *LEF1*, and *MMPs* accompanied by cytoplasmic retention of YAP/TAZ and reduced expression of *CTGF*, *TGM2*, *LOX*, and *PAI-1*, resolution of adverse actin remodeling and softening of TM cells.](iovs-61-6-30-f009){#fig9}
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